Buscar
Emergent BioSolutions Inc
EBSAñadir a la lista de seguimiento
7.220USD
-0.050-0.69%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
372.53MCap. mercado
PérdidaP/E TTM
Más Datos de Emergent BioSolutions Inc Compañía
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Información de Emergent BioSolutions Inc
Símbolo de cotizaciónEBS
Nombre de la empresaEmergent BioSolutions Inc
Fecha de salida a bolsaNov 15, 2006
Director ejecutivoPapa (Joseph C)
Número de empleados900
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 15
Dirección300 Professional Dr
CiudadGAITHERSBURG
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal20879
Teléfono12406313200
Sitio Webhttps://emergentbiosolutions.com/
Símbolo de cotizaciónEBS
Fecha de salida a bolsaNov 15, 2006
Director ejecutivoPapa (Joseph C)
Ejecutivos de Emergent BioSolutions Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
267.95K
-1.48%
Ms. Jessica Perl
Ms. Jessica Perl
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
165.29K
+63.09%
Ms. Coleen Glessner
Ms. Coleen Glessner
Executive Vice President - Quality and Ethics and Compliance
Executive Vice President - Quality and Ethics and Compliance
153.92K
-1.31%
Mr. William Hartzel
Mr. William Hartzel
Senior Vice President - Manufacturing and Bioservices
Senior Vice President - Manufacturing and Bioservices
145.03K
-1.20%
Dr. Simon C Lowry, M.D.
Dr. Simon C Lowry, M.D.
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
116.59K
+85.86%
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
114.67K
+22.10%
Mr. Ronald B. Richard
Mr. Ronald B. Richard
Independent Director
Independent Director
89.36K
+28.36%
Mr. Marvin L. White
Mr. Marvin L. White
Independent Director
Independent Director
79.44K
+31.90%
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Director
Independent Director
59.03K
+16.71%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
267.95K
-1.48%
Ms. Jessica Perl
Ms. Jessica Perl
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
165.29K
+63.09%
Ms. Coleen Glessner
Ms. Coleen Glessner
Executive Vice President - Quality and Ethics and Compliance
Executive Vice President - Quality and Ethics and Compliance
153.92K
-1.31%
Mr. William Hartzel
Mr. William Hartzel
Senior Vice President - Manufacturing and Bioservices
Senior Vice President - Manufacturing and Bioservices
145.03K
-1.20%
Dr. Simon C Lowry, M.D.
Dr. Simon C Lowry, M.D.
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
116.59K
+85.86%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Emergent BioSolutions Inc?
Los cinco principales accionistas de Emergent BioSolutions Inc son: Mr. Joseph C. (Joe) Papa
¿Cuántas instituciones poseen acciones de Emergent BioSolutions Inc (EBS)?
A fecha de 2026Q1, 412 instituciones poseen acciones de Emergent BioSolutions Inc, con un valor de mercado combinado de aproximadamente 42.30M, lo que representa el 81.98% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -3370363.00.
¿Cuál es la mayor fuente de ganancias de Emergent BioSolutions Inc?
El 2026Q1, el segmento empresarial Commercial Product sales generó la ganancia más alta para Emergent BioSolutions Inc, ascendiendo a 223.30M y representando el 30.06% de la ganancia total.